U.S. patent application number 12/173235 was filed with the patent office on 2008-11-06 for aromatic sulfenates for type i phototherapy.
Invention is credited to Samuel I. Achilefu, Joseph E. Bugaj, Gary L. Cantrell, Richard B. Dorshow, Raghavan Rajagopalan.
Application Number | 20080275017 12/173235 |
Document ID | / |
Family ID | 25410176 |
Filed Date | 2008-11-06 |
United States Patent
Application |
20080275017 |
Kind Code |
A1 |
Rajagopalan; Raghavan ; et
al. |
November 6, 2008 |
AROMATIC SULFENATES FOR TYPE I PHOTOTHERAPY
Abstract
Novel sulfenate derivatives and their bioconjugates for
phototherapy of tumors and other lesions. The sulfenates of the
present invention are designed to absorb low-energy ultraviolet,
visible, or near-infrared (NIR) region of the electromagnetic
spectrum. The phototherapeutic effect is caused by direct
interaction of free radicals, the reactive intermediate produced
upon photofragmentation of the sulfenate moiety, with the tissue of
interest.
Inventors: |
Rajagopalan; Raghavan;
(Beechwood, OH) ; Cantrell; Gary L.; (Troy,
IL) ; Achilefu; Samuel I.; (St. Louis, MO) ;
Bugaj; Joseph E.; (St. Charles, MO) ; Dorshow;
Richard B.; (St. Louis, MO) |
Correspondence
Address: |
THOMPSON HINE L.L.P.;Intellectual Property Group
P.O. BOX 8801
DAYTON
OH
45401-8801
US
|
Family ID: |
25410176 |
Appl. No.: |
12/173235 |
Filed: |
July 15, 2008 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11276971 |
Mar 20, 2006 |
7427657 |
|
|
12173235 |
|
|
|
|
09898887 |
Jul 3, 2001 |
7235685 |
|
|
11276971 |
|
|
|
|
Current U.S.
Class: |
514/182 ;
514/297; 514/454; 514/618 |
Current CPC
Class: |
A61K 41/0057 20130101;
A61P 35/00 20180101 |
Class at
Publication: |
514/182 ;
514/618; 514/297; 514/454 |
International
Class: |
A61K 31/565 20060101
A61K031/565; A61K 31/165 20060101 A61K031/165; A61K 31/473 20060101
A61K031/473; A61K 31/352 20060101 A61K031/352 |
Claims
1. A method of using a compound, the method comprising:
administering the compound to a patient; and exposing the
administered compound to light, wherein the compound is of the
following formula ##STR00004## and wherein: E is a somatostatin
receptor binding molecule, an ST receptor binding molecule, a
neurotensin receptor binding molecule, a bombesin receptor binding
molecule, a cholecystokinin receptor binding molecule, a steroid
receptor binding molecule, a carbohydrate receptor binding
molecule, or dihydroxyindolecarboxylic acid; X is --(R.sup.5)NOC--,
--(R.sup.5)NOCCH.sub.2O--, --(R.sup.5)NOCCH.sub.2CH.sub.2O--, or
--HNC(.dbd.S)NH; each of R.sup.1 to R.sup.5 is independently
hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 polyhydroxyalkyl, or
C1-C10 polyalkoxyalkyl; Q is a single bond or an alkenyl, aromatic,
or heteroaromatic radical derived from an olefin, a benzene, a
naphthalene, a naphthoquinone, a fluorene, an anthracene, an
anthraquinone, a phenanthrene, a tetracene, a naphthacenedione, a
pyridine, a quinoline, an isoquinoline, an indole, an isoindole, a
pyrrole, an imidiazole, an oxazole, a thiazole, a pyrazole, a
pyrazine, a purine, a benzimidazole, a furan, a benzofuran, a
dibenzofuran, a carbazole, an acridine, an acridone, a
phenanthridine, a thiophene, a benzothiophene, a dibenzothiophene,
a xanthene, a xanthone, a flavone, a coumarin, or an anthracycline;
and Ar is an aromatic or heteroaromatic radical derived from a
benzene, a naphthalene, a naphthoquinone, a diphenylmethane, a
fluorene, an anthracene, an anthraquinone, a phenanthrene, a
tetracene, a naphthacenedione, a pyridine, a quinoline, an
isoquinoline, an indole, an isoindole, a pyrrole, an imidiazole, an
oxazole, a thiazole, a pyrazole, a pyrazine, a purine, a
benzimidazole, a furan, a benzofuran, a dibenzofuran, a carbazole,
an acridine, an acridone, a phenanthridine, a thiophene, a
benzothiophene, a dibenzothiophene, a xanthene, a xanthone, a
flavone, a coumarin, or an anthracycline.
2. The method of claim 1, wherein E is a somatostatin receptor
binding molecule.
3. The method of claim 1, wherein E is an ST receptor binding
molecule.
4. The method of claim 1, wherein E is a neurotensin receptor
binding molecule.
5. The method of claim 1, wherein E is a bombesin receptor binding
molecule.
6. The method of claim 1, wherein E is a cholecystokinin receptor
binding molecule.
7. The method of claim 1, wherein E is a steroid receptor binding
molecule.
8. The method of claim 1, wherein E is a carbohydrate receptor
binding molecule.
9. The method of claim 1, wherein E is dihydroxyindolecarboxylic
acid.
10. The method of claim 1, wherein X is --(R.sup.5)NOC--.
11. The method of claim 1, wherein X is
--(R.sup.5)NOCCH.sub.2O--.
12. The method of claim 1, wherein X is
--(R.sup.5)NOCCH.sub.2CH.sub.2O--.
13. The method of claim 1, wherein X is --HNC(.dbd.S)NH.
14. The method of claim 1, wherein Q is a single bond.
15. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an olefin.
16. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a benzene.
17. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a naphthalene.
18. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a fluorine.
19. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an anthracene.
20. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an anthraquinone.
21. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a phenanthrene.
22. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a tetracene.
23. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a naphthacenedione.
24. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a pyridine.
25. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a quinoline.
26. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an isoquinoline.
27. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an indole.
28. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an isoindole.
29. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a pyrrole.
30. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an imidiazole.
31. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an oxazole.
32. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a thiazole.
33. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a pyrazole.
34. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a pyrazine.
35. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a purine.
36. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a benzimidazole.
37. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a furan.
38. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a benzofuran.
39. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a dibenzofuran.
40. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a carbazole.
41. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an acridine.
42. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an acridone.
43. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a phenanthridine.
44. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a thiophene.
45. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a benzothiophene.
46. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a dibenzothiophene.
47. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a xanthene.
48. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a xanthone.
49. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a flavone.
50. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from a coumarin.
51. The method of claim 1, wherein Q is an alkenyl, aromatic, or
heteroaromatic radical derived from an anthracycline.
52. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a benzene.
53. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a naphthalene.
54. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a naphthoquinone.
55. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a diphenylmethane.
56. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a fluorine.
57. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an anthracene.
58. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a anthraquinone.
59. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a phenanthrene.
60. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a tetracene.
61. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a naphthacenedione.
62. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a pyridine.
63. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a quinoline.
64. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an isoquinoline.
65. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an indole.
66. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an isoindole.
67. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a pyrrole.
68. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an imidiazole.
69. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an oxazole.
70. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a thiazole.
71. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a pyrazole.
72. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a pyrazine.
73. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a purine.
74. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a benzimidazole.
75. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a furan.
76. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a benzofuran.
77. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a dibenzofuran.
78. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a carbazole.
79. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an acridine.
80. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an acridone.
81. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a phenanthridine.
82. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a thiophene.
83. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a benzothiophene.
84. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a dibenzothiophene.
85. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a xanthene.
86. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a xanthone.
87. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a flavone.
88. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from a coumarin.
89. The method of claim 1, wherein Ar is an aromatic or
heteroaromatic radical derived from an anthacyline.
90. The method of claim 1, wherein the light is between about 300
nm and about 950 nm wavelength.
91. The method of claim 1, wherein the compound is administered in
a range of about 0.1 mg/kg body weight to about 500 mg/kg body
weight.
92. The method of claim 1, wherein the compound is administered in
a range of about 0.5 mg/kg body weight to about 2 mg/kg body
weight.
93. The method of claim 1, wherein the compound is administered as
part of a biocompatible composition.
94. The method of claim 92, wherein the compound is administered at
a concentration range of about 1 nM to about 0.5M.
Description
[0001] This application is a Continuation of U.S. patent
application Ser. No.11/276,971 filed Mar. 20, 2006, now pending,
and U.S. patent application Ser. No.09/898,887 filed Jul. 3, 2001,
now U.S. Pat. No. 7,235,685, each of which is expressly
incorporated by reference herein in its entirety.
FIELD OF THE INVENTION
[0002] This invention relates to novel dye-sulfenate compositions
and phototherapeutic procedures using these compositions.
BACKGROUND OF THE INVENTION
[0003] The use of visible and near-infrared (NIR) light in clinical
practice is growing rapidly. Compounds absorbing or emitting in the
visible or long-wavelength (UV-A, >350 nm) region of the
electromagnetic spectrum are potentially useful for optical
tomographic imaging, endoscopic visualization, and phototherapy.
However, a major advantage of biomedical optics lies in its
therapeutic potential. Phototherapy has been demonstrated to be a
safe and effective procedure for the treatment of various surface
lesions, both external and internal. Its efficacy is akin to
radiotherapy, but it advantageously lacks the harmful radiotoxicity
to critical non-target organs.
[0004] Phototherapy has been in existence for many centuries and
has been used to treat various skin surface ailments. As early as
1400 B.C. in India, plant extracts (psoralens), in combination with
sunlight, were used to treat vitiligo. In 1903, Von Tappeiner and
Jesionek, used eosin as a photosensitizer for treating skin cancer,
lupus of the skin, and condylomata of female genitalia. Over the
years, the combination of psoralens and ultraviolet A (low-energy)
radiation has been used to treat a wide variety of dermatological
diseases and manifestations including psoriasis, parapsoriasis,
cutaneous T-cell lymphoma, eczema, vitiligo, areata, and neonatal
bilirubinemia. Although the potential of cancer phototherapy has
been recognized since the early 1900s, systematic studies to
demonstrate safety and efficacy began only in 1967 with the
treatment of breast carcinoma. In 1975, Dougherty et al.
conclusively established that long-term cure is possible with
photodynamic therapy (PDT). Currently, phototherapeutic methods are
also being investigated for the treatment of some cardiovascular
disorders such as atherosclerosis and vascular restenosis, for the
treatment of rheumatoid arthritis, and for the treatment of some
inflammatory diseases such as Chron's disease.
[0005] Phototherapeutic procedures require photosensitizers (i.e.
chromophores) having high absorptivity. These compounds should
preferably be chemically inert and become activated only upon
irradiation with light of an appropriate wavelength. Selective
tissue injury can be induced with light when photosensitizers bind
to the target tissues, either directly or through attachment to a
bioactive carrier. Furthermore, if the photosensitizer is also a
chemotherapeutic agent (e.g., anthracycline antitumor agents), then
an enhanced therapeutic effect can be attained. The key
requirements for the design of effective phototherapeutic agents
are: (a) large molar extinction coefficients, (b) long triplet
lifetimes, (c) high yields of singlet oxygen and/or other reactive
intermediates, viz., free radicals, nitrenes, carbenes, or
open-shell ionic species such as carbonium ions and the like, (d)
efficient energy or electron transfer to cellular components, (e)
low tendency to form aggregation in an aqueous milieu, (f)
efficient and selective targeting of lesions, (g) rapid clearance
from the blood and non-target tissues, (h) low systemic toxicity,
and (i) lack of mutagenicity.
[0006] Photosensitizers operate via two distinct mechanisms, termed
Types 1 and 2. The type 1 mechanism is shown in the following
scheme:
hv
SENSITIZER.fwdarw.(SENSITIZER)*
(SENSITIZER)*+TISSUE.fwdarw.TISSUE DAMAGE
Type 1 mechanisms involve direct energy or electron transfer from
the photosensitizer to the cellular components thereby causing cell
death. Type 2 mechanisms involve two distinct steps, as shown in
the following scheme:
hv
SENSITIZER.fwdarw.(SENSITIZER)*
(SENSITIZER)*+.sup.3O.sub.2 (Triplet Oxygen).fwdarw..sup.1O.sub.2
(Singlet Oxygen)
.sup.1O.sub.2 (Singlet Oxygen)+TISSUE.fwdarw.TISSUE DAMAGE
In the first step, singlet oxygen is generated by energy transfer
from the triplet excited state of the photosensitizer to the oxygen
molecules surrounding the tissues. In the second step, collision of
singlet oxygen with the tissues promotes tissue damage. In both
Type 1 and Type 2 mechanisms, the photoreaction proceeds via the
lowest triplet state of the sensitizer. Hence, a relatively long
triplet lifetime is required for effective phototherapy. In
contrast, a relatively short triplet lifetime is required to avoid
photodamage to the tissue caused by photosensitizers.
[0007] The biological basis of tissue injury brought about by tumor
phototherapeutic agents has been the subject of intensive study.
Various reasonable biochemical mechanisms for tissue damage have
been postulated even though the type and number of photosensitizers
employed in these studies are relatively small. These biochemical
mechanisms are as follows: a) cancer cells upregulate the
expression of low density lipoprotein (LDL) receptors, and
photodynamic therapy (PDT) agents bind to LDL and albumin
selectively; (b) porphyrin-like substances are selectively taken up
by proliferative neovasculature; (c) tumors often contain increased
number of lipid bodies and are thus able to bind to hydrophobic
photosensitizers; (d) a combination of "leaky" tumor vasculature
and reduced lymphatic drainage causes porphyrin accumulation; (e)
tumor cells may have increased capabilities for phagocytosis or
pinocytosis of porphyrin aggregates; (f) tumor associated
macrophages may be largely responsible for the concentration of
photosensitizers in tumors; and (g) cancer cells may undergo
apoptosis induced by photosensitizers. Among these mechanisms, (f)
and (g) are the most general and, of these two alternatives, there
is a general consensus that (f) is the most likely mechanism by
which the phototherapeutic effect of porphyrin-like compounds is
induced.
[0008] Most of the currently known photosensitizers are commonly
referred to as photodynamic therapy (PDT) agents and operate via
the Type 2 mechanism. For example, Photofrin II (a hematoporphyrin
derivative) has been recently approved by the United States Food
and Drug Administration for the treatment of bladder, esophageal,
and late-stage lung cancers. However, Photofrin II has been shown
to have several drawbacks: a low molar absorptivity (.epsilon.=3000
M-1), a low singlet oxygen quantum yield (.PHI.=0.1), chemical
heterogeneity, aggregation, and prolonged cutaneous
photosensitivity. Hence, there has been considerable effort in
developing safer and more effective photosensitizers for PDT which
exhibit improved light absorbance properties, better clearance, and
decreased skin photosensitivity compared to Photofrin II. These
include monomeric porphyrin derivatives, corrins, cyanines,
phthalocyanines, phenothiazines, rhodamines, hypocrellins, and the
like. However, these phototherapeutic agents also mainly operate
via the Type 2 mechanism.
[0009] Surprisingly, there has not been much attention directed at
developing Type 1 phototherapeutic agents, despite the fact that
the Type 1 mechanism appears to be inherently more efficient than
the Type 2 mechanism. First, unlike Type 2, Type 1 photosensitizers
do not require oxygen for causing cellular injury. Second, the Type
1 mechanism involves two steps (photoexcitation and direct energy
transfer), whereas the Type 2 mechanism involves three steps
(photoexcitation, singlet oxygen generation, and energy transfer).
Furthermore, certain tumors have hypoxic regions, which renders the
Type 2 mechanism ineffective. However, in spite of the drawbacks
associated with the Type 2 mechanism, only a small number of
compounds have been developed that operate through the Type 1
mechanism, e.g. anthracycline antitumor agents.
[0010] Thus, there is a need to develop effective phototherapeutic
agents that operate via the Type 1 mechanism. Phototherapeutic
efficacy can be further enhanced if the excited state
photosensitizers can generate reactive intermediates such as free
radicals, nitrenes, carbenes, and the like, which have much longer
lifetimes than the excited chromophore and have been shown to cause
considerable cell injury.
SUMMARY OF THE INVENTION
[0011] The present invention discloses novel aromatic sulfenates
that react mainly by a type 1 mechanism for phototherapy of tumors
and other lesions. More specifically, the present invention
discloses sulfenates having the formula,
##STR00001##
wherein E is selected from the group consisting of somatostatin,
ST, neurotensin, bombesin, cholecystokinin, steroid, and
carbohydrate receptor binding molecules, and
dihydroxyindolecarboxylic acid. X is selected from the group
consisting of --(R5)NOC--, --(R5)NOCCH2O--, --(R5)NOCCH2CH2O--, and
--HNC(.dbd.S)NH. R1 to R5 are independently selected from the group
consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10
polyhydroxyalkyl and C1-C10 polyalkoxyalkyl. Q is either a single
bond or an alkenyl, aromatic, or heteroaromatic radical derived
from a compound selected from the group consisting of olefins,
benzenes, naphthalenes, naphthoquinones, fluorines, anthracenes,
anthraquinones, phenanthrenes, tetracenes, naphthacenediones,
pyridines, quinolines, isoquinolines, indoles, isoindoles,
pyrroles, imidiazoles, oxazoles, thiazoles, pyrazoles, pyrazines,
purines, benzimidazoles, furans, benzofurans, dibenzofurans,
carbazoles, acridines, acridones, phenanthridines, thiophenes,
benzothiophenes, dibenzothiophenes, xanthenes, xanthones, flavones,
coumarins, and anthacylines; and Ar is an aromatic or
heteroaromatic radical derived from a compound selected from the
group consisting of benzenes, naphthalenes, naphthoquinones,
diphenylmethanes, fluorenes, anthracenes, anthraquinones,
phenanthrenes, tetracenes, naphthacenediones, pyridines,
quinolines, isoquinolines, indoles, isoindoles, pyrroles,
imidiazoles, oxazoles, thiazoles, pyrazoles, pyrazines, purines,
benzimidazoles, furans, benzofurans, dibenzofurans, carbazoles,
acridines, acridones, phenanthridines, thiophenes, benzothiophenes,
dibenzothiophenes, xanthenes, xanthones, flavones, coumarins, and
anthacylines.
[0012] The present invention also discloses a method of performing
a therapeutic procedure using the sulfenate compounds of the
present invention. An effective amount of a sulfenate
photosensitizer having the formula,
##STR00002##
is administered to a subject. E is selected from the group
consisting of somatostatin, ST, neurotensin, bombesin,
cholecystokinin, steroid, and carbohydrate receptor binding
molecules, and dihydroxyindolecarboxylic acid. X is selected from
the group consisting of --(R5)NOC--, --(R5)NOCCH2O--,
--(R5)NOCCH2CH2O--, and --HNC(.dbd.S)NH, R1 to R5 are independently
selected from the group consisting of hydrogen, C1-C10 alkyl,
C5-C10 aryl, C1-C10 polyhydroxyalkyl, and C1-C10 polyalkoxyalkyl. Q
is either a single bond or an alkenyl, aromatic, or heteroaromatic
radical derived from a compound selected from the group consisting
of olefins, benzenes, naphthalenes, naphthoquinones, fluorenes,
anthracenes, anthraquinones, phenanthrenes, tetracenes,
naphthacenediones, pyridines, quinolines, isoquinolines, indoles,
isoindoles, pyrroles, imidiazoles, oxazoles, thiazoles, pyrazoles,
pyrazines, purines, benzimidazoles, furans, benzofurans,
dibenzofurans, carbazoles, acridines, acridones, phenanthridines,
thiophenes, benzothiophenes, dibenzothiophenes, xanthenes,
xanthones, flavones, coumarins, and anthacylines; Ar is an aromatic
or heteroaromatic radical derived a compound selected from the
group consisting of benzenes, naphthalenes, naphthoquinones,
diphenylmethanes, fluorenes, anthracenes, anthraquinones,
phenanthrenes, tetracenes, naphthacenediones, pyridines,
quinolines, isoquinolines, indoles, isoindoles, pyrroles,
imidiazoles, oxazoles, thiazoles, pyrazoles, pyrazines, purines,
benzimidazoles, furans, benzofurans, dibenzofurans, carbazoles,
acridines, acridones, phenanthridines, thiophenes, benzothiophenes,
dibenzothiophenes, xanthenes, xanthones, flavones, coumarins, and
anthacylines. The photosensitizer is allowed to accumulate in
target tissue which is exposed to light of wavelength between 300
and 950 nm with sufficient power and fluence rate to perform the
phototherapeutic procedure. The photoexcitation of the aromatic
chromophore effects rapid intramolecular energy transfer to the
sulfenate group, resulting in bond rupture and the production of
two reactive free radicals which cause cellular injury.
[0013] These and other advantages and embodiments of the inventive
compounds and methods will be apparent in view of the following
figures, description, and examples.
BRIEF DESCRIPTION OF THE DRAWINGS
[0014] FIG. 1 is a schematic mechanism for activation of the
inventive compounds.
[0015] FIG. 2 is a schematic mechanism for the synthesis of a diol
in accordance with the present invention.
[0016] FIG. 3 is a schematic mechanism for the synthesis of an
acridone derivative.
[0017] FIG. 4 is a schematic mechanism for the synthesis of an
acridine sulfenate derivative.
[0018] FIG. 5 is a schematic mechanism for the synthesis of an
anthraquinone-sulfate derivative.
[0019] FIG. 6 is a schematic mechanism for the synthesis of a
xanthene derivative.
[0020] FIG. 7 is a schematic mechanism for the synthesis of a
steroid-photosensitizer conjugate derivative.
[0021] FIG. 8 is a schematic mechanism for delivering a
photosensitizer to the site of a lesion by attaching it to a
biosynthetic intermediate.
DETAILED DESCRIPTION
[0022] The present invention discloses novel sulfenate derivatives
and their bioconjugates for phototherapy of tumors and other
lesions.
[0023] The compounds have the general formula,
##STR00003##
wherein E is either a hydrogen atom or is selected from the group
consisting of antibodies, peptides, peptidomimetics, carbohydrates,
glycomimetics, drugs, hormones, or nucleic acids; X is selected
from the group consisting of --(R.sup.5)NOC--,
--(R.sup.5)NOCCH.sub.2O--, --(R.sup.5)NOCCH.sub.2CH.sub.2O--,
--OCN(R.sup.5)--, --HNC(.dbd.S)NH--, and HNC(.dbd.O)NH--; Q is
either a single bond or an alkenyl, aromatic, or heteroaromatic
radical derived from a compound selected from the group consisting
of olefins, benzenes, naphthalenes, naphthoquinones, fluorenes,
anthracenes, anthraquinones, phenanthrenes, tetracenes,
naphthacenediones, pyridines, quinolines, isoquinolines, indoles,
isoindoles, pyrroles, imidiazoles, oxazoles, thiazoles, pyrazoles,
pyrazines, purines, benzimidazoles, furans, benzofurans,
dibenzofurans, carbazoles, acridines, acridones, phenanthridines,
thiophenes, benzothiophenes, dibenzothiophenes, xanthenes,
xanthones, flavones, coumarins, and anthacylines; R.sup.1 to
R.sup.5 are independently selected from the group consisting of
hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 polyhydroxyalkyl, and
C1-C10 polyalkoxyalkyl; and Ar is an aromatic or heteroaromatic
radical derived from a compound selected from the group consisting
of benzenes, naphthalenes, naphthoquinones, diphenylmethanes,
fluorenes, anthracenes, anthraquinones, phenanthrenes, tetracenes,
naphthacenediones, pyridines, quinolines, isoquinolines, indoles,
isoindoles, pyrroles, imidiazoles, oxazoles, thiazoles, pyrazoles,
pyrazines, purines, benzimidazoles, furans, benzofurans,
dibenzofurans, carbazoles, acridines, acridones, phenanthridines,
thiophenes, benzothiophenes, dibenzothiophenes, xanthenes,
xanthones, flavones, coumarins, and anthacylines.
[0024] In one embodiment, sulfenates according to the present
invention have the general formula shown above, wherein E is
selected from the group consisting of somatostatin, ST,
neurotensin, bombesin, cholecystokinin, steroid, and carbohydrate
receptor binding molecules, and dihydroxyindolecarboxylic acid; X
is selected from the group consisting of --(R.sup.5)NOC--,
--(R.sup.5)NOCCH.sub.2O--, --(R.sup.5)NOCCH.sub.2CH.sub.2O--, and
--HNC(.dbd.S)NH; Q is a single bond or an olefinic or aromatic
radical derived from a compound selected from the group consisting
of alkenes, benzenes, furans, pyrroles, imidazoles, oxazoles,
thiophenes, anthraquinones, quinolines, isoquinolines, indoles,
acridines, acridones, phenanthridines, xanthenes, xanthones, and
anthacylines; R.sup.1 to R.sup.5 are independently selected from
the group consisting of hydrogen, C1-C10 alkyl, C5-C10 aryl, and
C1-C10 polyhydroxyalkyl; and Ar is an aromatic or heteroaromatic
radical derived from a compound selected from the group consisting
of benzenes, diphenylmethanes, fluorenes, anthraquinones,
naphthacenediones, pyridines, quinolines, isoquinolines, indoles,
acridines, acridones, phenanthridines, xanthenes, xanthones, and
anthacylines.
[0025] In an alternative embodiment, sulfenates according to the
present invention have the general formula shown above, wherein E
is selected from the group consisting of somatostatin, ST,
neurotensin, bombesin, cholecystokinin (CCK), steroid, and
carbohydrate receptor binding molecules; X is --(R.sup.5)NOC--, and
--(R.sup.5)NOCCH.sub.2O--; Q is a single bond or is selected from
the group consisting of benzenes, furans, pyrroles, oxazoles,
acridines, acridones, xanthenes, xanthones, and anthracyclines;
R.sup.1 to R.sup.5 are independently selected from the group
consisting of hydrogen, and C1-C10 alkyl; and Ar is an aromatic or
heteroaromatic radical derived from a compound selected from the
group consisting of benzenes, diphenylmethanes, fluorenes,
anthraquinones, naphthacenediones, pyridines, quinolines, indoles,
acridines, acridones, phenanthridines, xanthenes, xanthones, and
anthracyclines.
[0026] These compounds operate mainly by a Type I mechanism as
shown in FIG. 1, wherein --O--SR is the sulfenate moiety that
produces free radicals upon photoactivation, and Ar is an aromatic
chromophore that undergoes photosensitization. Aliphatic and
aromatic sulfenates can be used for phototherapy, although aromatic
sulfenates have better material handling properties, as is well
known in the art (J. Amaudrut and O. Wiest, The thermal
sulfenate-sulfoxide rearrangement: A radical pair mechanism.
Journal of the American Chemical Society, 2000, 122, 3367-3374,
which is expressly incorporated by reference herein in its
entirety). L is a linker between the chromophore and the epitope.
Epitope (E) is a particular region of the molecule that is
recognized by, and binds to, the target site on the cell. E is
usually, but not always, associated with biomolecules which include
hormones, amino acids, peptides, peptidomimetics, proeins,
nucleosides, nucleotides, nucleic acids, enzymes, carbohydrates,
glycomimetics, lipids, albumins, mono- and polyclonal antibodies,
receptors, inclusion compounds such as cyclodextrins, and receptor
binding molecules. Specific examples of biomolecules include
steroid hormones for the treatment of breast and prostate lesions,
somatostatin, bombesin, and neurotensin receptor binding molecules
for the treatment of neuroendocrine tumors, cholecystokinin
receptor binding molecules for the treatment of lung cancer; ST
receptor and carcinoembryonic antigen (CEA) binding molecules for
the treatment of colorectal cancer, dihydroxyindolecarboxylic acid
and other melanin producing biosynthetic intermediates for
melanoma, integrin receptor and atherosclerotic plaque binding
molecules for the treatment of vascular diseases, and amyloid
plaque binding molecules for the treatment of brain lesions.
Biomolecules for use in the present invention may also include
synthetic polymers. Examples of synthetic polymers include
polyaminoacids, polyols, polyamines, polyacids, oligonucleotides,
aborols, dendrimers, and aptamers. Coupling of diagnostic and
radiotherapeutic agents to biomolecules can be accomplished by
methods well known in the art as disclosed in Hnatowich et al.,
Radioactive Labeling of Antibody: A simple and efficient method.
Science, 1983, 220, 613-615; A. Pelegrin et al.,
Photoimmunodiagnosis with antibody-fluorescein conjugates: in vitro
and in vivo preclinical studies. Journal of Cellular Pharmacology,
1992, 3,141-145; and U.S. Pat. No. 5,714,342, each of which are
expressly incorporated by reference herein in their entirety.
Successful specific targeting of fluorescent dyes to tumors using
antibodies and peptides for diagnostic imaging of tumors has been
demonstrated by us and others, for example, S. A. Achilefu et al.,
Novel receptor-targeted fluorescent contrast agents for in vivo
tumor imaging, Investigative Radiology, 2000, 35(8), 479-485; B.
Ballou et al., Tumor labeling in vivo using cyanine-conjugated
monoclonal antibodies, Cancer Immunology and Immunotherapy, 1995,
41, 247-263; K. Licha et al., New contrast agent for optical
imaging: acid-cleavable conjugates of cyanine dyes with
biomolecules, In Biomedical Imaging: Reporters, Dyes, and
Instrumentation, D. J. Bornhop, C. Contag, and E. M. Sevick-Muraca
(Eds.), Proceedings of SPIE, 1999, 3600, 29-35, each of which are
expressly incorporated by reference herein in their entirety.
Therefore, the inventive receptor-targeted phototherapeutic agents
are expected to be effective in the treatment of various
lesions.
[0027] In the process outlined in FIG. 1, the photoexcitation of
the aromatic chromophore effects rapid intramolecular energy
transfer to the sulfenate group, resulting in bond rupture and
production of two reactive free radicals which cause cellular
injury.
[0028] For targeting purposes, external attachment of an epitope is
used. If the aromatic sulfenate compounds themselves preferentially
accumulate in the target tissue, however, an additional binding
group may not be needed. For example, if Ar is an anthracycline
moiety, it will bind to cancer cells directly and would not require
an epitope for targeting purposes.
[0029] The synthesis of sulfenate derivatives is accomplished by
the method disclosed in D. L. Pasto and F. Cottard, Demonstration
of the synthetic utility of the generation of alkoxy radicals by
the photo-induced, homolytic dissociation of alkyl
4-nitrobenzenesulfenates, Tetrahedron Letters, 1994, 35(25),
4303-4306, which is expressly incorporated by reference herein in
its entirety. This method generally involves the condensation of
sulfenyl chlorides with alcohols in the presence of an organic
base. The sulfenate derivatives of the present invention contain
additional functionalities that can be used to attach various types
of biomolecules, synthetic polymers, and organized aggregates for
selective delivery to various organs or tissues of interest.
[0030] A diol 1 is prepared by the reaction of methyl magnesium
bromide with methyl 4-hydroxybenzoate. Referring to FIG. 2,
alkylation of the resulting phenol with methyl bromoacetate,
condensation of the tertiary alcohol with 4-nitrobenzenesulfenyl
chloride, and saponification of the ester affords an intermediate
acid 2. This acid 2 is then converted to the corresponding active
ester using N-hydroxysuccimide (NHS) and dicyclohexylcarbodiimide
(DCC). The active ester can be attached to any desired biomolecule
of interest to form an aromatic sulfenate 3. Alternatively, the
acid 2 can also be directly condensed with any biomolecule using
automated peptide synthesizer. Specifically, the biomolecule of the
present invention pertains to those binding to colorectal,
cervical, ovarian, lung, and neuroendocrine tumors. These include
somatostatin, cholecystokinin, bombesin, neuroendrocrine, and ST
receptor binding compounds.
[0031] An acridone derivative is prepared according to FIG. 3. The
starting material 4 is prepared according to a standard method
known to one of skill in the art, as disclosed in K. Matsumura,
1-Aminoacridine-4-carboxylic acid., Journal of the American
Chemical Society, 1938, 32, 591-592, which is expressly
incorporated by reference herein in its entirety. An aminoacridone
4 is converted to a phenol by a standard method of diazotization of
the amino group followed by displacement of the diazonium group
with sodium hydroxide. The phenol 5 is converted to the
corresponding p-nitrobenzenesulfenate and then conjugated to the
biomolecules directly using an automated peptide synthesizer, or
indirectly by the active ester route, to form the inventive
acridine derivative 6.
[0032] A typical preparation of acridine-sulfenate derivative is
outlined in FIG. 4. A thiol 7 is prepared from the known starting
material 9-chloroacridone. It is converted to the corresponding
sulfenyl chloride, condensed with methyl
3-hydroxy-3-methylbutyrate, and saponified to acid 8. The
sulfenate-acid can be condensed with the desired biomolecules by
the process previously described.
[0033] The anthraquinone-sulfenate derivatives can be synthesized
according to FIG. 5. A diacid chloride 10 is reacted with a lactone
11 under Friedel-Crafts conditions followed by saponification to
the corresponding hydroxyanthraquinone 12. It is then condensed
with p-nitrobenzenesulfenyl chloride and conjugated to the desired
biomolecule directly to form an inventive derivative 14.
Alternatively, the lactone 10 could be hydrolyzed to the acid and
then coupled to the biomolecule by conventional methods.
[0034] The xanthene derivative can be prepared according to FIG. 6.
A xanthone benzyl ether 15 is prepared from the known
4-hydroxyxanthone by alkylation with benzylbromide. The compound 15
was converted to the ether 16 in three steps: bromination, Grignard
reaction with ethylformate, and Grignard reaction with
methylmagnesium bromide. Deprotection of the t-butyl group with HCl
followed by alkylation with methyl bromoacetate provides a tertiary
alcohol 17. The tertiary alcohol 17 is then condensed with
p-nitrobenzenesulfenyl chloride, saponified, and conjugated to the
desired biomolecules mentioned previously.
[0035] The novel compositions of the present invention may vary
widely depending on the contemplated application. For tumors, the
biomolecule is selected from the class of tumor markers including,
but not limited to, somatostatin, bombesin, neurotensin,
cholecystokinin, ST, estrogen, and progesterone receptor binding
compounds. For vascular lesions, the biomolecule may be selected
from the class of integrins, selectins, vascular endothelial growth
factor, fibrins, tissue plasminogen activator, thrombin, LDL, HDL,
Sialyl LewisX and its mimics, and atherosclerotic plaque binding
compounds. A typical synthetic scheme of a steroid-photosensitizer
conjugate is shown in FIG. 7. Estrone is protected as the t-butyl
ether 19 and reduced with sodium borohydride to a mono protected
estradiol 20, which is then condensed with p-nitrobenzenesulfenyl
chloride. Deprotection of the t-butyl group yields the
steroid-photosensitizer conjugate 21.
[0036] As previously described, some compounds accumulate in tumors
or other lesions without the assistance of a bioactive carrier.
Administration of .delta.-aminolevulinic acid, an intermediate in
porphyrin biosynthesis, results in a two-fold uptake of porphyrins
in tumors compared to normal tissues. Similarly, administration of
dihydroxyindole-2-carboxylic acid, an intermediate in melanin
biosynthesis, produces substantially enhanced levels of melanin in
melanoma cells compared to normal cells. Thus, a photosensitizer
may be delivered to the site of lesion by attaching it to a
biosynthetic intermediate, as shown in FIG. 8. The mono sulfenate
23 is prepared by the reaction of p-nitrobenzenesulfenyl chloride
22 with ethylene glycol and is condensed with an indole derivative
24. Hydrolysis of the diacetate provides the conjugate 25.
[0037] Methods of performing therapeutic procedures with the
inventive compounds are also disclosed. An effective amount of the
inventive compounds in a pharmaceutically acceptable formulation is
administered to a patient. For example, parenteral administration
advantageously contains a sterile aqueous solution or suspension of
the photosensitizer in a concentration ranging from about 1 nM to
about 0.5 M. Preferred parenteral formulations have a concentration
of 1 .mu.M to 10 mM. Such solutions also may contain
pharmaceutically acceptable buffers, emulsifiers, surfactants, and,
optionally, electrolytes such as sodium chloride. Formulations for
enteral administration may vary widely, as is well known in the
art. In general, such formulations are liquids, which include an
effective amount of the complexes in aqueous solution or
suspension. Such enteral compositions may optionally include
buffers, surfactants, emulsifiers, thixotropic agents, and the
like. Compounds for oral administration may also contain flavoring
agents and other ingredients for enhancing their organoleptic
qualities. Formulations for topical delivery may also contain
liquid or semisolid excipients to assist in the penetration of the
photosensitizer. The compounds may also be delivered in an aerosol
spray. The dose of the photosensitizer may vary from 0.1 to 500
mg/kg body weight, preferably from 0.5 to 2 mg/kg body weight. The
photosensitizer is allowed to accumulate in the region of interest,
followed by illumination with the light of wavelength 300 to 1200
nm, preferably 350 to 850 nm, at the site of the lesion. If the
lesion is on the skin surface, the photosensitizer can be directly
illuminated; otherwise, endoscopic catheters equipped with a light
source may be employed to achieve phototherapeutic effect. The
intensity, power, duration of illumination, and the wavelength of
the light may vary widely depending on the location and site of the
lesions. The wavelength of light may vary from 300 to 1200 nm. The
fluence rate is preferably, but not always, kept below 200 mW/cm2
to minimize thermal effects. Appropriate power depends on the size,
depth, and the pathology of the lesion. The novel inventive
compounds have broad clinical utility which includes, but is not
limited to, phototherapy of tumors, inflammatory processes, and
impaired vasculature.
[0038] The inventive compounds can be formulated into diagnostic or
therapeutic compositions for enteral, parenteral, topical, or
cutaneous administration. Topical or cutaneous delivery of the
photosensitizer may also include aerosol formulation, creams, gels,
solutions, etc. The compounds are administered in doses effective
to achieve the desired diagnostic or therapeutic effect. Such doses
may vary widely depending upon the particular complex employed, the
organs or tissues to be examined, the equipment employed in the
clinical procedure, the efficacy of the treatment achieved, and the
like. These compositions contain an effective amount of the
phototherapeutic agent along with conventional pharmaceutical
carriers and excipients appropriate for the type of administration
contemplated. These compositions may also include stabilizing
agents and skin penetration enhancing agents.
[0039] The following example illustrates a specific embodiment of
the invention pertaining to the preparation and properties of a
typical bioconjugate derived from bombesin, a bioactive peptide,
and a phototherapeutic molecule, sulfenate.
EXAMPLE
Synthesis of Sulfenate-bombesin (7-14) Conjugate
[0040] The peptide is prepared by fluorenylmethoxycarbonyl (Fmoc)
solid phase peptide synthesis strategy with a commercial peptide
synthesizer from Applied Biosystems (Model 432A SYNERGY Peptide
Synthesizer). The first peptide cartridge contains Wang resin
pre-loaded with an amide resin on 25-.mu.mole scale. The amino acid
cartridges are placed on the peptide synthesizer and the product is
synthesized from the C- to the N-terminal position. Coupling of the
Fmoc-protected amino acids (75 .mu.mol) to the resin-bound free
terminal amine (25 82 mol) is carried out with
2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU, 75 .mu.mol)/N-hydroxybenzotriazole
(HOBt, 75 .mu.mol). Each Fmoc protecting group on the solid support
was removed with 20% piperidine in dimethylformamide before the
subsequent amino acid was coupled to it. The last cartridge
contains sulfenate acid, which is coupled to the peptide
automatically, thus avoiding the need for post-synthetic
manipulations.
[0041] After the synthesis is completed, the product is cleaved
from the solid support with a cleavage mixture containing
trifluoroacetic acid (85%):water (5%):phenol (5%):thioanisole (5%)
for 6 hours. The peptide-sulfenate conjugate is precipitated with
t-butyl methyl ether and lyophilized in water:acetonitrile (2:3)
mixture. The conjugate is purified by HPLC and analyzed with LC/MS.
The sulfenate-bombesin (7-14) conjugate has the following molecular
structure:
p-azidotetrafluorobenzoyl-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2.
[0042] As would be apparent to skilled artisans, various changes
and modifications are possible and are contemplated within the
scope of the invention described. It should be understood that the
embodiments of the present invention shown and described in the
specification are only specific embodiments of the inventors who
are skilled in the art and are not limiting in any way. Therefore,
various changes, modifications or alterations to those embodiments
may be made or resorted to without departing from the spirit of the
invention and the scope of the following claims. The references
cited are expressly incorporated by reference. For example,
although the compositions of the present invention are primarily
directed at therapy, most of the compounds containing polycyclic
aromatic chromophores can also be used for optical diagnostic
imaging purposes.
* * * * *